News Channels

17 Jun 2020 Armata Pharmaceuticals Announces $15 Million Award from the U.S. Department of Defense (DoD) for Development of Bacteriophage Therapy to Treat S. aureus Bacteremia Infections
17 Jun 2020 CORAT Therapeutics Takes Over the Fast Track Development of a Novel COVID-19 Antibody Drug Program
17 Jun 2020 Sagimet Announces Positive Topline Results in 12-week NASH Phase 2 Clinical Trial of FASN Inhibitor TVB-2640
17 Jun 2020 ASC40 (TVB-2640) Significantly Reduced Liver Fat With a 61% Responder Rate in Phase 2 NASH Trial
17 Jun 2020 RemeGen Co., Ltd. Announced New RC48-ADC Data in Patients with Advanced Gastric Cancer at ASCO
17 Jun 2020 Lassen Therapeutics Launches to Discover and Develop Novel Antibody Therapeutics Including Lead Program Targeting IL-11 to Treat Fibrosis and Oncology
17 Jun 2020 Atara Biotherapeutics Announces First Patient Enrolled in Randomized Placebo-Controlled Study of Allogeneic T-cell Therapy ATA188 in Progressive Forms of Multiple Sclerosis
17 Jun 2020 FDA Approves Second Biomarker-Based Indication for Merck’s KEYTRUDA® (pembrolizumab), Regardless of Tumor Type
17 Jun 2020 Ubiquigent Continues Drug Discovery Collaboration With Bristol Myers Squibb
17 Jun 2020 Recordati: Isturisa® (osilodrostat) phase III LINC-4 trial meets its primary endpoint in Cushing’s disease
17 Jun 2020 FDA Approves First Treatment for Adult Onset Still’s Disease, a Severe and Rare Disease
17 Jun 2020 Novartis Cosentyx® receives FDA approval for new indication to treat active non-radiographic axial spondyloarthritis
17 Jun 2020 FDA approves gemtuzumab ozogamicin for CD33-positive AML in pediatric patients
17 Jun 2020 Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19
17 Jun 2020 Merck and Pfizer’s SGLT2 Inhibitor STEGLATROTM (ertugliflozin) Meets Primary Endpoint in VERTIS CV Trial for Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
16 Jun 2020 Saiba AG Selects AGC Biologics to Develop and Produce COVID-19 Vaccine
16 Jun 2020 eTheRNA Raises EUR 34 Million in Series B Financing to Accelerate Multiple mRNA Therapeutic Development Programs Through to Clinical Proof of Concept
16 Jun 2020 Exicure Announces First Patient Dosed in Phase 2 Merkel Cell Carcinoma Trial of Cavrotolimod (AST-008)
16 Jun 2020 Immunomic Therapeutics Enters into License Agreement with Ichor Medical Systems to Use Electroporation (EP) Delivery Technology in Phase I Study of DNA Vaccine Therapy, ITI-1001
16 Jun 2020 C4 Therapeutics Raises $170 Million Financing to Bring Robust Pipeline of Protein Degraders to Clinical Proof-of-Concept and to Advance Proprietary Platform

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up